Johnson & Johnson Makes Headline Again

In terms of business, this year is turning out to be one of the worst for pharmaceutical giant, Johnson & Johnson (NYSE:JNJ). Multiple times, throughout the year, they have had to recall several drugs. Some were due to packaging and others due to a chemical imbalance. Today Johnson & Johnson is in the news again but this time they are not recalling any items. Instead, the Food and Drug Administration, has requested that the company immediately stop their trial of a new pain medication they are developing. The new pain medication in question seems to have several side effects, including bone damage.

The FDA is extremely strict when it comes to testing drugs and any other items that are consumable by people. Johnson & Johnson has already taken their advice and has stopped the trial as of immediate effect. These types of problems are common within the pharmaceutical industry and it helps them improve the quality of their drugs. However for Johnson & Johnson, this just means another problem they have to overcome. At this current state the company stands to lose millions in sales and their loyal customer base. In the coming year, they will need to focus on how to improve their products and hold on to the market they already have a good reputation in.